UCB (UCB) and Biogen (BIIB) announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol in people living with moderate-to-severe systemic lupus erythematosus. Dapirolizumab pegol, in addition to standard-of-care treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity after 48 weeks versus placebo in addition to SOC. Also, clinical improvements were observed among key secondary endpoints measuring disease activity and flares.
Based on the successful outcome of the PHOENYCS GO study, the companies are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.